Illumina, Inc. (NASDAQ:ILMN) today announced the opening of its Solutions Center on the Genopole Campus in Évry, near Paris. The leading-edge customer training center will offer demonstrations, instruction, and education in the latest genomics technologies from Illumina for up to 1,000 scientists a year, providing direct links to Illumina’s global network of facilities and in-house experts. The center will also accommodate Illumina’s first commercial office on the European continent to (...)
PEP-Therapy, a biotechnology company, member of the Genopole biocluster, which develops innovative peptides as targeted therapies, has achieved a second fundraising of €1.2 million. This investment, made by the Quadrivium 1 seed fund and Dr Bernard Majoie, and based on the results obtained so far, will enable PEP-Therapy to continue the development of its products portfolio, especially to undertake the regulatory development of PEP-010 associated with its biomarker to foresee the efficacy of (...)
ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, announced today that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology and research in genomics and genetics. The new laboratories brings Enterome closer to its existing and potential new partners and provides opportunities to extend its scientific expertise and network to develop its business (...)
Malakoff – FRANCE, August 29th, 2017 – THERACLION (Alternext, FR0010120402 – ALTHE, PEA PME eligible), a company specialized in leading-edge medical equipment for echotherapy, today announces the results published in the « Radiology » journal on Graves’ disease treatment by echotherapy using Echopulse. The study is entitled : “Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves’ Disease : Preliminary Experience in a Prospective Study” and is available (...)
Evry, France, 11 July 2017, 8h00 - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced its sales for the first half of 2017. Strong growth in genomics services for clinical research and microbiology
Leaders of Sustainable Biofuels welcome French company Global Bioenergies as new member : “Significant increase in interest in advanced biofuels evident as the discussions on future EU policy are soon entering decision-making time” Leaders of Sustainable Biofuels coalition welcomes French company Global Bioenergies as new member of the coalition promoting advanced biofuels as fast track solution to cut transport emissions. Global Bioenergies develops innovative processes converting a broad (...)
Theraclion (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announce that the first patients were treated in the U.S. pivotal clinical trial to evaluate the safety and efficacy of Echopulse® echotherapy as a non-invasive treatment of breast fibroadenomas (BFAs).
Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that it has raised €1,5M from CapDecisif Management. Acticor Biotech had already secured €1,4M in the first closing, which brings the total amount invested to €2,9M.
Laboratoire Cerba and METAFORA biosystems are proud to announce the availability of the innovative test METAglut1 in routine biology to help diagnose the GLUT1 deficiency syndrome (GLUT1-DS)
Global Bioenergies (Alternext Paris : ALGBE) has finalized the acquisition of Syngip B.V. at the close of its extraordinary shareholders’ meeting today. Syngip B.V. is a start-up based in the Netherlands that specializes in converting third-generation resources into fuels and materials.